Compare ADMA Biologics Inc (ADMA) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Equinor ASA — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Equinor ASA trades at $34.36 (market cap $77.42B). The key difference: Equinor ASA is far larger — about 36.3× ADMA Biologics Inc's market cap, and Equinor ASA pays a 4.48% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EQNR | |
|---|---|---|
Market Cap | $2.13B | $77.42B |
Sector | Health | Energy |
52-Week High | $20.38 | $42.40 |
52-Week Low | $7.60 | $22.41 |
Enterprise Value | $2.20B | $89.19B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Equinor (EQNR) trades at $33.91, up 5.84% today, with a bearish technical signal despite recent earnings beats. The company shows solid cash flow from operations of $20.0B in 2025 and maintains a low EV/EBITDA of 2.21, but net income has declined to $5.04B. Recent strategic moves include acquiring BP's stake in Bay du Nord and expanding Norwegian gas production, while exiting non-core ventures like Japan offshore wind.
EQNR offers value with low valuation multiples and shareholder returns via dividends and buybacks, but faces risks from volatile energy prices and declining profitability. Analyst sentiment is mixed with 30% buy ratings, reflecting cautious optimism amid execution challenges and macroeconomic pressures on the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
